Continued Anticomplement Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome
Therapeutics · 2024
DOI: 10.3390/therapeutics1010005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutics, 2024. Verfasst von Natasha Venugopal und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Complement-mediated hemolytic uremic syndrome (CM-HUS), formerly known as atypical HUS, is a rare but potentially fatal thrombotic microangiopathy (TMA) characterized by the triad of thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and acute kidney injury. It is primarily caused by complement dysregulation. The condition can progress to end-stage renal disease (ESRD), often necessitating kidney transplant. In rare instances, it can develop in post-renal-transplant patients.
Methods
Here, we present the cases of two patients with ESRD status post kidney transplant who presented with thrombocytopenia, anemia, and acute kidney injury. In both cases, work-up was suggestive of CM-HUS, and stabilization was achieved with eculizumab.
Discussion
The pathogenesis of CM-HUS involves dysregulation of the complement system, and complement inhibitors such as eculizumab can be used for initial management and relapse. The relapse rate following eculizumab treatment can range from 20 to 67%. Patients with a history of kidney transplant are more prone to relapse than those with native kidneys. Re-treatment with complement inhibitors has proven effective in managing relapses, and long-term continuation of complement inhibitor medications is recommended to prevent recurrence.
Conclusions
CM-HUS is rare, especially in post-transplant patients, and can be potentially fatal. It is crucial for clinicians to recognize and treat this condition promptly. Management often involves complement inhibitors. The risk of relapse is particularly high in patients with a history of kidney transplant, but long-term continuation of these medications can prevent relapse.
Zitieren
APA
Venugopal, N., Polimera, H. V., Santucci, J., Washburn, E., & Federici, E. (2024). Continued Anticomplement Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome. Therapeutics. https://doi.org/10.3390/therapeutics1010005
Vancouver
Venugopal N, Polimera HV, Santucci J, Washburn E, Federici E. Continued Anticomplement Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome. Therapeutics. 2024. doi:10.3390/therapeutics1010005
BibTeX
@article{Venugopal2024,
author = {Venugopal, Natasha and Polimera, Hyma V. and Santucci, Jessica and Washburn, Erik and Federici, Elizabeth},
title = {Continued Anticomplement Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome},
journal = {Therapeutics},
year = {2024},
doi = {10.3390/therapeutics1010005}
}
EUVIMED